PLK1 and neoplasm: Results in the global population showed that metastasis-free survival (MFS) of patients with high PLK1-expressing tumours (5-year MFS 68.4%; 10-year MFS 58.5%; 15-year MFS 49.8%) was shorter than that of patients with low PLK1-expressing tumours (5-year MFS 88.7%; 10-year MFS 77.4%; 15-year MFS 74.4%) (P < 0.0001; Fig. 5c).